Navigation Links
Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
Date:10/29/2013

income) expense, net:  Interest expense, net920920  Foreign exchange transaction loss, net281281  Gain on sale of investment(1,459)1,459-Other (income) expense, net(258)-1,459--1,201Income before taxes30,84914,0722,5412,609-50,071Taxes on income(6,971)4,42573078811,50110,473Net income $
37,820$
9,647$
,811$
,821$
(11,501)$
39,598Basic earnings per share$
.70$
.18$
.03$
.03$
(0.21)$
.74Weighted average shares outstanding - basic53,687,74853,687,74853,687,74853,687,74853,687,74853,687,748Diluted earnings per share$
.69$
.17$
.03$
.03$
(0.21)$
.72Weighted average shares outstanding - diluted55,201,55255,201,55255,201,55255,201,55255,201,55255,201,552(1) Represents costs incurred to better align capacity to preclinical market demand and reduce cost structure.(2) Consists of costs associated with the settlement of an inventory supply agreement ($4,000) and a gain on the sale of an investment $1,459.(3) Represents results of operations at sites where wind-down activities have commenced.(4) Primarily represents favorable resolutions of income tax matters. 

 COVANCE INC.GAAP to Pro Forma ReconciliationYTD Q3 2013(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring
and Other Cost
Reduction
Activities (1)Other
Items (2)Pro FormaNet revenues$  1,779,219$  1,779,219Reimbursable out-of-pocket expenses146,142146,142Total revenues1,925,361--1,925,361Costs and expenses:  Cost of revenue1,255,3161,255,316  Reimbursable out-of-pocket expenses146,142146,142  Selling, general and administrative266,448(14,576)251,872  Depreciation and amortization95,072(2,500)92,572Total costs and expenses1,762,978(17,076)-1,745,902Income from operations162,38317,076-179,459Other (income) expense, net:  Interest expense, net2,6342,634  Foreign exchange transaction loss, net1,9111,911  Gain on sal
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Covance To Present At The Leerink Swann Global Healthcare Conference
8. Covance To Present At The Citi 2013 Global Healthcare Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
10. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
11. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, today announced its attendance at the ... be held in Chicago, Illinois June 19th-23rd. ... #735 on June 20th-22nd. Individuals attending the meeting are ...
... SAN DIEGO, June 10, 2011 Gen-Probe Incorporated (NASDAQ: ... at the William Blair & Company 31st Annual Growth Stock ... p.m. Central Time (5 p.m. Eastern Time).  The presentation is ... a link on the investors section of Gen-Probe,s website at ...
Cached Medicine Technology:DATATRAK Exhibiting at 47th Annual DIA Meeting 2Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference 2
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/24/2014)... 2014 (HealthDay News) -- If you are a high-risk ... are not treated by a cardiologist, new research suggests. ... cardiologists left town for annual professional meetings, Harvard researchers ... who were admitted to a teaching hospital during one ... percent died when these meetings were not taking place. ...
(Date:12/22/2014)... As early as thirty, gravity begins to ... form of “jowls." The dreaded droopiness usually appears around ... line or smile lines. Aging can be fought with ... the deep facial tissues descend, jowls inevitably appear. , ... can be used under the skin to fill natural ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... York, New York (PRWEB) December 22, 2014 ... are a staple of the season. Many may be thinking ... in a span of a few weeks. Health Republic Insurance ... help of Registered Dietitian, Andrea Chernus, to provide some smart ... eat and stay healthy. , 1)    Avoid arriving at a holiday ...
Breaking Medicine News(10 mins):Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2
... of metabolic protein architecture and their advance offers ... ,,Researchers at the University of Illinois ... online edition of the Proceedings of the National Academy ... techniques of phylogenetic analysis developed in the past decade ...
... that it has a mix of properties that would ... matrix with metallic clusters that can absorb light, ... and then destroy those targeted cells with a laser. ... nanocomposite (DNC) matrix containing silver clusters that can be ...
... recently identified genetic marker for prostate cancer is linked ... ,These findings ultimately will aid the development ... susceptible to this aggressive cancer, Northwestern researchers said. Knowing ... doctors in how they treat the cancer. ...
... at Nokia have developed software that transforms a cellphone into ... lightning strike. ,A lightning bolt is an ... frequencies between 10 hertz and five gigahertz. However, the distribution ... is. ,According to the scientists, the multiple receivers ...
... toxic substance, made by certain types of bacteria found in house ... condition eczema or wheezing in children if they are exposed to ... Endotoxin is an element of the cell wall of gram-negative bacteria, ... when the bacteria dies or is damaged. ,The new ...
... The Most Powerful Weight-Loss Formula on Earth!" ... common in many parts of the world and thousands of ... is that there are few regulations to govern this booming ... ones that exist. ,Weight loss is a desperate ...
Cached Medicine News:Health News:Protein Folds Research Offers Insight into Metabolic Evolution 2Health News:Protein Folds Research Offers Insight into Metabolic Evolution 3Health News:Nanocomposite Labeled Cancer Cells Targeted and Destroyed by Using Lasers 2Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... in determining functionality of a patient's ... courses of treatment for patients receiving ... and autoimmune dieseases. Kit 030 ... diseases giving rise to high titers ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Medicine Products: